Cargando…

Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release

OBJECTIVE: To evaluate over 108 weeks the effect of phentermine and topiramate extended release (PHEN/TPM ER) treatment on progression to type 2 diabetes and/or cardiometabolic disease in subjects with prediabetes and/or metabolic syndrome (MetS) at baseline. RESEARCH DESIGN AND METHODS: Subanalysis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garvey, W. Timothy, Ryan, Donna H., Henry, Robert, Bohannon, Nancy J.V., Toplak, Hermann, Schwiers, Michael, Troupin, Barbara, Day, Wesley W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2014
Materias:	Current Concepts of Type 2 Diabetes Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392900/ https://www.ncbi.nlm.nih.gov/pubmed/24103901 http://dx.doi.org/10.2337/dc13-1518

Ejemplares similares

Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
por: Allison, David B., et al.
Publicado: (2012)

Genetic Risk of Progression to Type 2 Diabetes and Response to Intensive Lifestyle or Metformin in Prediabetic Women With and Without a History of Gestational Diabetes Mellitus
por: Sullivan, Shannon D., et al.
Publicado: (2014)

The Reality of Type 2 Diabetes Prevention
por: Kahn, Richard, et al.
Publicado: (2014)

A “Spoonful of Sugar” and the Realities of Diabetes Prevention!
por: Cefalu, William T.
Publicado: (2014)

Dietary Sugar and Body Weight: Have We Reached a Crisis in the Epidemic of Obesity and Diabetes?: Health Be Damned! Pour on the Sugar
por: Bray, George A., et al.
Publicado: (2014)

Substitution among milk and yogurt products and the risk of incident type 2 diabetes in the EPIC‐NL cohort
por: Stuber, J. M., et al.
Publicado: (2020)

Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017)

The Vildagliptin Experience — 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration
por: Foley, James E, et al.
Publicado: (2017)

Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin — Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes
por: Strain, William David, et al.
Publicado: (2017)

Clinical Safety and Tolerability of Vildagliptin — Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance
por: Mathieu, Chantal, et al.
Publicado: (2017)

Effects of potato resistant starch intake on insulin sensitivity, related metabolic markers and appetite ratings in men and women at risk for type 2 diabetes: a pilot cross‐over randomised controlled trial
por: Sanders, L. M., et al.
Publicado: (2020)

Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity
por: Jordan, Jens, et al.
Publicado: (2014)

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study(1)(2)(3)
por: Garvey, W Timothy, et al.
Publicado: (2012)

Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
por: Sweeting, Arianne N, et al.
Publicado: (2014)

Phentermine and topiramate for the management of obesity: a review
por: Cosentino, Gina, et al.
Publicado: (2011)

Phentermine-topiramate: First combination drug for obesity
por: Singh, Jagjit, et al.
Publicado: (2015)

Cardiovascular Safety During and After Use of Phentermine and Topiramate
por: Ritchey, Mary E, et al.
Publicado: (2018)

Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management
por: Garvey, William Timothy
Publicado: (2013)

Extended family history of type 1 diabetes in HLA‐predisposed children with and without islet autoantibodies
por: Kuusela, Salla, et al.
Publicado: (2020)

Beta-cell Insufficiency
por: Kalra, Sanjay, et al.
Publicado: (2017)

Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity
por: Shin, Jin Hee, et al.
Publicado: (2013)

A Narrative Review: Phentermine and Topiramate for the Treatment of Pediatric Obesity
por: Kim, Anthony, et al.
Publicado: (2023)

Combination of venlafaxine and phentermine/topiramate induced psychosis: A case report
por: Homola, Jaclyn, et al.
Publicado: (2018)

Phentermine–topiramate extended release for the dual treatment of obesity and sleep-related eating disorder: a case report
por: Grunvald, Eduardo, et al.
Publicado: (2022)

Response to Comment on Bress et al. Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. Diabetes Care 2017;40:1401–1408
por: Bress, Adam P., et al.
Publicado: (2018)

Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release
por: Guo, Fangjian, et al.
Publicado: (2017)

Formulary Management of 2 New Agents: Lorcaserin and Phentermine/Topiramate for Weight Loss
por: Kelly, Elizabeth M., et al.
Publicado: (2013)

Clinical Effectiveness of Intraoperative Tranexamic Acid Use in Shoulder Surgery: A Systematic Review and Meta-analysis
por: Hartland, Alexander W., et al.
Publicado: (2021)

Mixed‐meal tolerance test to assess residual beta‐cell secretion: Beyond the area‐under‐curve of plasma C‐peptide concentration
por: Ruan, Yue, et al.
Publicado: (2019)

Increased tissue factor activity promotes thrombin generation at type 1 diabetes onset in children
por: Jasser‐Nitsche, Hildegard, et al.
Publicado: (2020)

Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials—GPPAD‐02 study design and first results
por: Winkler, Christiane, et al.
Publicado: (2019)

Celiac disease can be predicted by high levels of tissue transglutaminase antibodies in children and adolescents with type 1 diabetes
por: Cerqueiro Bybrant, Mara, et al.
Publicado: (2020)

Human plasma‐derived alpha(1)‐proteinase inhibitor in patients with new‐onset type 1 diabetes mellitus: A randomized, placebo‐controlled proof‐of‐concept study
por: Lagarde, William H., et al.
Publicado: (2020)

Viral infection‐related gene upregulation in monocytes in children with signs of β‐cell autoimmunity
por: Valta, Milla, et al.
Publicado: (2022)

Associations between deduced first islet specific autoantibody with sex, age at diagnosis and genetic risk factors in young children with type 1 diabetes
por: Ilonen, Jorma, et al.
Publicado: (2022)

Antibiotic treatment during early childhood and risk of type 1 diabetes in children: A national birth cohort study
por: Antvorskov, Julie Christine, et al.
Publicado: (2020)

HbA1c as a time predictive biomarker for an additional islet autoantibody and type 1 diabetes in seroconverted TEDDY children
por: Salami, Falastin, et al.
Publicado: (2022)

Insulin resistance relates to DKA severity and affects insulin requirement in children with type 1 diabetes at onset
por: Mastromauro, Concetta, et al.
Publicado: (2022)

Trochleoplasty in major trochlear dysplasia: current concepts
por: Beaufils, Philippe, et al.
Publicado: (2012)

Clinical examination of the knee: know your tools for diagnosis of knee injuries
por: Rossi, Roberto, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_9s0pnn6oq27d1l2ns8o0noq4v3